This report from Life Science Intelligence provides the latest market data for the Global Tricuspid Valve Repair Market. Information covered by this report includes:
The global market for tricuspid valve repair devices is expected to reach an estimated $90.4 million in 2020 and is projected to increase at a CAGR (2020-2024) of 27.3%. Product segments covered by this report include tricuspid valve annuloplasty rings and transcatheter tricuspid valve repair devices.
This report covers the impact of COVID-19 on the tricuspid valve repair market, including a recent forecast from 2020 to 2024. COVID-19 has also impacted leading competitors, such as Abbott, Edwards Lifesciences, Medtronic, LivaNova, and others. The report provides insights into trends, drivers, and limiters of the tricuspid valves market, as well as highlights potential opportunities.
The tricuspid valve repair market witnessed a minor decline due to the COVID-19 pandemic. The decline in procedures was very minimal and is expected to rebound by Q4 2020 and reach pre-COVID-19 levels in the first half of 2021.
Tricuspid regurgitation is a life-threatening condition if left untreated and is estimated to affect close to 60-80% of the population. Due to the complexity of the tricuspid valve, when compared with the mitral and aortic valves, medical therapy has been the standard of care for many years. The success of the transcatheter approaches for treating aortic and mitral valve disease has also impacted the treatment of tricuspid regurgitation via a transcatheter approach.